The development of acamprosate as a treatment against alcohol relapse

Bibliography

• World Health Organization. Global status report on alcohol and health. WHO, Geneva, Switzerland; 2014
   Google Scholar
• Gmel G, Rehm J. Harmful alcohol use. Alcohol Res Health 2003;27:52-62
   PubMedGoogle Scholar
• O’Connor PG, Gottlieb LD, Kraus ML, et al. Social and clinical features as predictors of outcome in outpatient alcohol withdrawal. J Gen Intern Med 1991;6:312-16
   PubMed Web of Science ®Google Scholar
• Ludwig AM, Wikler A, Stark LH. The first drink: psychobiological aspects of craving. Arch Gen Psychiatry 1974;30:539-47
   PubMed Web of Science ®Google Scholar
• McCusker CG, Brown K. Alcohol-predictive cues enhance tolerance to and precipitate "craving" for alcohol in social drinkers. J Stud Alcohol 1990;51:494-9
   PubMed Web of Science ®Google Scholar
• McCusker CG, Brown K. Cue-exposure to alcohol-associated stimuli reduces autonomic reactivity, but not craving and anxiety, in dependent drinkers. Alcohol Alcohol 1995;30:319-27
   PubMed Web of Science ®Google Scholar
• Tiffany ST, Conklin CA. A cognitive processing model of alcohol craving and compulsive alcohol use. Addiction 2000;95(Suppl 2):S145-53
   PubMed Web of Science ®Google Scholar
• O’Brien CP, Childress AR, Ehrman R, et al. Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol 1998;12:15-22
   PubMed Web of Science ®Google Scholar
• Litten RZ, Egli M, Heilig M, et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 2012;17:513-27
   PubMed Web of Science ®Google Scholar
• Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482-90
   PubMed Web of Science ®Google Scholar
• O’Brien CP. Treatment of alcoholism as a chronic disorder. In: Jansson B, Jonvall H, Rydberg U, Terenius L, Vallee BL, editors. Toward a molecular basis of alcohol use and abuse. Birkhauser, Basel, Switzerland; 1994. p. 349-59
   Google Scholar
• Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag 2007;3:741-9
   PubMedGoogle Scholar
• Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985;1(8436):1014-16
   PubMed Web of Science ®Google Scholar
• Yahn SL, Watterson LR, Olive MF. Safety and efficacy of acamprosate for the treatment of alcohol dependence. Subst Abuse 2013;6:1-12
   PubMedGoogle Scholar
• Boismare F, Daoust M, Moore N, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984;21:787-9
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. JAMA 2006;295:2003-17
   PubMed Web of Science ®Google Scholar
• Feeney GF, Connor JP. Acamprosate and naltrexone are safe and effective but have low compliance rates for people with alcohol dependence. Evid Based Mental Health 2005;8:14
   PubMedGoogle Scholar
• Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60:92-9
   PubMed Web of Science ®Google Scholar
• Mann KF. Acamprosate: clinical data. In: Spanagel R, Mann K, editors. Drugs for relapse prevention of alcoholism. Birkhauser, Basel, Switzerland; 2005. p. 85-93
   Google Scholar
• Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003;13:469-75
   PubMed Web of Science ®Google Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-19
   PubMed Web of Science ®Google Scholar
• Durlach J. Novel derivatives of 3-aminopropanesulfonic acid having a reinforced activity on membrane. United States Patent Office. US4355043; 1982
   Google Scholar
• Andrews PR, Johnston GA. GABA agonists and antagonists. Biochem Pharmacol 1979;28:2697-702
   PubMed Web of Science ®Google Scholar
• Mann K, Kiefer F, Spanagel R, et al. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008;32:1105-10
   PubMed Web of Science ®Google Scholar
• Zornoza T, Cano MJ, Polache A, et al. Pharmacology of acamprosate: an overview. CNS Drug Rev 2003;9:359-74
   PubMedGoogle Scholar
• Forest Laboratories. Campral prescribing information. 2004
   Google Scholar
• Zornoza T, Cano-Cebrian MJ, Nalda-Molina R, et al. Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (caco-2 cell monolayers) and in vivo models. Eur J Pharm Sci 2004;22:347-56
   PubMed Web of Science ®Google Scholar
• Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, editor. Acamprosate in relapse prevention of alcoholism. Springer, Berlin; 1996. p. 47-64
   Google Scholar
• Zornoza T, Cano-Cebrian MJ, Hipolito L, et al. Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats. Biopharm Drug Dispos 2006;27:305-11
   PubMed Web of Science ®Google Scholar
• Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001;62(Suppl 20):42-8
   PubMed Web of Science ®Google Scholar
• Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35:331-45
   PubMed Web of Science ®Google Scholar
• Chabenat C, Chretien P, Daoust M, et al. Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate. Methods Find Exp Clin Pharmacol 1988;10:311-17
   PubMed Web of Science ®Google Scholar
• Spanagel R, Vengeliene V, Jandeleit B, et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 2014;39:783-91
   PubMed Web of Science ®Google Scholar
• Le Magnen J, Tran G, Durlach J, et al. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987;4:97-102
   PubMed Web of Science ®Google Scholar
• Gewiss M, Heidbreder C, Opsomer L, et al. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 1991;26:129-37
   PubMed Web of Science ®Google Scholar
• Montgomery KC. The effect of the hunger and thirst drives upon exploratory behavior. J Comp Physiol Psychol 1953;46:315-19
   PubMed Web of Science ®Google Scholar
• Spanagel R. How to measure relapse in animals. In: Spanagel R, Mann K, editors. Drugs for relapse prevention of alcoholism. Birkhauser, Basel, Switzerland; 2005. p. 13-21
   Google Scholar
• Sinclair JD, Senter RJ. Development of an alcohol-deprivation effect in rats. Q J Stud Alcohol 1968;29:863-7
   PubMedGoogle Scholar
• Salimov RM, Salimova NB. The alcohol-deprivation effect in hybrid mice. Drug Alcohol Depend 1993;32:187-91
   PubMed Web of Science ®Google Scholar
• Sinclair AJ. The alcohol-deprivation effect in monkeys. Psychonom Sci 1971;25:21-2
   Google Scholar
• Burish TG, Maisto SA, Cooper AM, et al. Effects of voluntary short-term abstinence from alcohol on subsequent drinking patterns of college students. J Stud Alcohol 1981;42:1013-20
   PubMed Web of Science ®Google Scholar
• Larimer ME, Palmer RS, Marlatt GA. Relapse prevention: an overview of Marlatt’s cognitive-behavioral model. Alcohol Res Health 1999;23:151-60
   PubMedGoogle Scholar
• Spanagel R. Recent animal models of alcoholism. Alcohol Res Health 2000;24:124-31
   PubMedGoogle Scholar
• Markou A, Weiss F, Gold LH, et al. Animal models of drug craving. Psychopharmacology (Berl) 1993;112:163-82
   PubMed Web of Science ®Google Scholar
• Spanagel R, Holter SM, Allingham K, et al. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996;305:39-44
   PubMed Web of Science ®Google Scholar
• Heyser CJ, Schulteis G, Durbin P, et al. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998;18:125-33
   PubMed Web of Science ®Google Scholar
• Holter SM, Landgraf R, Zieglgansberger W, et al. Time course of camprosate action on operant ethanol self-administration after ethanol deprivation. Alcohol Clin Exp Res 1997;21:862-8
   PubMed Web of Science ®Google Scholar
• Czachowski CL, Legg BH, Samson HH. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcohol Clin Exp Res 2001;25:344-50
   PubMed Web of Science ®Google Scholar
• De Witte P, Bachteler D, Spanagel R. Acamprosate: preclinical data. In: Spanagel R, Mann K, editors. Drugs for relapse prevention of alcoholism. Birkhauser, Basel, Switzerland; 2005. p. 73-83
   Google Scholar
• Olive MF, Nannini MA, Ou CJ, et al. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol 2002;437:55-61
   PubMed Web of Science ®Google Scholar
• Dahchour A, De Witte P. Excitatory and inhibitory amino acid changes during repeated episodes of ethanol withdrawal: an in vivo microdialysis study. Eur J Pharmacol 2003;459:171-8
   PubMed Web of Science ®Google Scholar
• Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995;152:332-40
   PubMed Web of Science ®Google Scholar
• Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000;60:343-62
   PubMed Web of Science ®Google Scholar
• Spanagel R, Putzke J, Stefferl A, et al. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 1996;305:45-50
   PubMed Web of Science ®Google Scholar
• Spanagel R, Pendyala G, Abarca C, et al. The clock gene per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 2005;11:35-42
   PubMed Web of Science ®Google Scholar
• Pierrefiche O, Daoust M, Naassila M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology 2004;47:35-45
   PubMed Web of Science ®Google Scholar
• Naassila M, Hammoumi S, Legrand E, et al. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998;22:802-9
   PubMed Web of Science ®Google Scholar
• Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol 2000;394:221-31
   PubMed Web of Science ®Google Scholar
• al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998;22:810-14
   PubMed Web of Science ®Google Scholar
• Madamba SG, Schweitzer P, Zieglgansberger W, et al. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res 1996;20:651-8
   PubMed Web of Science ®Google Scholar
• Berton F, Francesconi WG, Madamba SG, et al. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABAB receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998;22:183-91
   PubMed Web of Science ®Google Scholar
• Harris BR, Gibson DA, Prendergast MA, et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res 2003;27:1724-35
   PubMed Web of Science ®Google Scholar
• Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002;26:1779-93
   PubMed Web of Science ®Google Scholar
• Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008;75:218-65
   PubMed Web of Science ®Google Scholar
• Koob GF, Mason BJ, De Witte P, et al. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 2002;26:586-92
   PubMed Web of Science ®Google Scholar
• al Qatari M, Khan S, Harris B, et al. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res 2001;25:1276-83
   PubMed Web of Science ®Google Scholar
• Blednov YA, Harris RA. Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol 2008;11:775-93
   PubMed Web of Science ®Google Scholar
• Reilly MT, Lobo IA, McCracken LM, et al. Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. Alcohol Clin Exp Res 2008;32:188-96
   PubMed Web of Science ®Google Scholar
• Bachteler D, Economidou D, Danysz W, et al. The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 2005;30:1104-10
   PubMed Web of Science ®Google Scholar
• Katner SN, Magalong JG, Weiss F. Reinstatement of alcohol-seeking behavior by drug-associated discriminative stimuli after prolonged extinction in the rat. Neuropsychopharmacology 1999;20:471-9
   PubMed Web of Science ®Google Scholar
• Epstein DH, Preston KL, Stewart J, et al. Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) 2006;189:1-16
   PubMed Web of Science ®Google Scholar
• Shaham Y, Shalev U, Lu L, et al. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 2003;168:3-20
   PubMed Web of Science ®Google Scholar
• Olive MF, Cleva RM, Kalivas PW, et al. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012;100:801-10
   PubMed Web of Science ®Google Scholar
• Backstrom P, Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 2006;31:778-86
   PubMed Web of Science ®Google Scholar
• Kufahl PR, Martin-Fardon R, Weiss F. Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR2/3 agonist LY379268 and increased functional activity of mGluR2/3 in rats with a history of ethanol dependence. Neuropsychopharmacology 2011;36:2762-73
   PubMed Web of Science ®Google Scholar
• Quertemont E, de Neuville J, De Witte P. Changes in the amygdala amino acid microdialysate after conditioning with a cue associated with ethanol. Psychopharmacology (Berl) 1998;139:71-8
   PubMed Web of Science ®Google Scholar
• Cole JC, Littleton JM, Little HJ. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology (Berl) 2000;147:403-11
   PubMed Web of Science ®Google Scholar
• Hillemand B, Lhuintre JP, Steru L, et al. Multicenter trial of calcium bis (acetylhomotaurinate) in treatment of alcohol dependence. Rev Alcohol 1989;34:9-28
   Google Scholar
• Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990;25:613-22
   PubMed Web of Science ®Google Scholar
• Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995;30:239-47
   PubMed Web of Science ®Google Scholar
• Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42
   PubMed Web of Science ®Google Scholar
• Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000;35:202-9
   PubMed Web of Science ®Google Scholar
• Barrias J, Chabac S, Ferreria L, et al. Acamprosate: multicenter portuguese efficacy and tolerance evaluation study. Psiquiatria Clin 1997;18:149-60
   Google Scholar
• Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-80
   PubMed Web of Science ®Google Scholar
• Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997;3:129-37
   Web of Science ®Google Scholar
• Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997;92:1537-46
   PubMed Web of Science ®Google Scholar
• Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997;171:73-7
   PubMed Web of Science ®Google Scholar
• Roussaeux JP, Hers D, Ferauge M. Does acamprosate influence alcohol consumption of weaned alcoholics? J Pharm Belg 1996;51:65-8
   PubMedGoogle Scholar
• Namkoong K, Lee BO, Lee PG, et al. Acamprosate in korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003;38:135-41
   PubMed Web of Science ®Google Scholar
• Chick J, Howlett H, Morgan MY, et al. United kingdom multicentre acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35:176-87
   PubMed Web of Science ®Google Scholar
• Pelc I, Le Bon O, Verbanck P, et al. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multi-centre study. In: Naranjo C, Sellers E, editors. Novel pharmacological interventions for alcoholism. Springer-Verlag. New York; 1992. p. 348-52
   Google Scholar
• Ladewig D, Knecht T, Leher P, et al. Acamprosate - a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 1993;50:182-8
   PubMedGoogle Scholar
• Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22:573-9
   PubMed Web of Science ®Google Scholar
• Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001;36:413-18
   PubMed Web of Science ®Google Scholar
• Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004;28:51-63
   PubMed Web of Science ®Google Scholar
• Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012;36:497-508
   PubMed Web of Science ®Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Sys Rev 2010(9):CD004332
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 2008;17:70-6
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati HM, Lynch KG, et al. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav 2009;34:581-6
   PubMed Web of Science ®Google Scholar
• Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006;101:1451-62
   PubMed Web of Science ®Google Scholar
• Berger L, Fisher M, Brondino M, et al. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the united states: a randomized, double-blind, placebo-controlled study. Alcohol Clin Exp Res 2013;37:668-74
   PubMed Web of Science ®Google Scholar
• Tolliver BK, Desantis SM, Brown DG, et al. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord 2012;14:54-63
   PubMed Web of Science ®Google Scholar
• Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606
   PubMed Web of Science ®Google Scholar
• Feeney GF, Connor JP, Young RM, et al. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres’ experience with pharmacotherapy. Alcohol Alcohol 2006;41:321-7
   PubMed Web of Science ®Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013;108:275-93
   PubMed Web of Science ®Google Scholar
• Mann K, Kiefer F, Smolka M, et al. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the predict study. Alcohol Clin Exp Res 2009;33:674-83
   PubMed Web of Science ®Google Scholar
• Mann K, Lemenager T, Hoffmann S, et al. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 2013;18:937-46
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Selby P, Negrete JC. Meta-analyses of placebo-controlled trials of acamprosate for the treatment of alcohol dependence: impact of the combined pharmacotherapies and behavior interventions study. J Addict Med 2009;3:74-82
   PubMed Web of Science ®Google Scholar
• Heilig M. Acamprosate: an alcoholism treatment that may not be what we thought. Neuropsychopharmacology 2014;39:781-2
   PubMed Web of Science ®Google Scholar
• Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Design 2010;16:2098-102
   PubMed Web of Science ®Google Scholar
• Tomek SE, Lacrosse AL, Nemirovsky NE, et al. NMDA receptor modulators in the treatment of drug addiction. Pharmaceuticals (Basel) 2013;6:251-68
   PubMedGoogle Scholar
• Kufahl PR, Barabas P, Halstengard C, et al. Potential use of antidepressants as therapies for drug use disorders. In: Ur-Rahman A, editor. Frontiers in clinical drug research - CNS and neurological disorders. Bentham Science Publishers; UAE: 2012. p. 1-37
   Google Scholar
• Cowen MS, Adams C, Kraehenbuehl T, et al. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addict Biol 2005;10:233-42
   PubMed Web of Science ®Google Scholar
• O’Brien CC. Experimental evidence in the treatment of alcoholism by intensive calcium therapy. J Am Osteopath Assoc 1952;51:393-4
   PubMedGoogle Scholar
• O’Brien CC. Intensive calcium therapy as an initial approach to the psychotherapeutic relationship in the rehabilitation of the complsive drinker. J Psychol 1964;57:125-9
   PubMed Web of Science ®Google Scholar
• Umhau JC, Momenan R, Schwandt ML, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 2010;67:1069-77
   PubMed Web of Science ®Google Scholar
• Dayas CV, Liu X, Simms JA, et al. Distinct patterns of neural activation associated with ethanol seeking: effects of naltrexone. Biol Psychiatry 2007;61:979-89
   PubMed Web of Science ®Google Scholar
• Ciccocioppo R, Lin D, Martin-Fardon R, et al. Reinstatement of ethanol-seeking behavior by drug cues following single versus multiple ethanol intoxication in the rat: effects of naltrexone. Psychopharmacology (Berl) 2003;168:208-15
   PubMed Web of Science ®Google Scholar
• Rimondini R, Arlinde C, Sommer W, et al. Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J 2002;16:27-35
   PubMed Web of Science ®Google Scholar
• Edwards G. History of prevention of relapse. In: Spanagel R, Mann K, editors. Drugs for relapse prevention of alcoholism. Birkhauser, Berlin; 2005. p. 1-13
   Google Scholar
• Levine HG. The discovery of addiction: changing conceptions of habitual drunkenness in America. J Stud Alcohol 1978;39:143-74
   PubMed Web of Science ®Google Scholar
• Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf 2010;9:177-88
   PubMed Web of Science ®Google Scholar
• Weiss RD, O’Malley S S, Hosking JD, et al. Do patients with alcohol dependence respond to placebo? Results from the COMBINE study. J Stud Alcohol Drugs 2008;69:878-84
   PubMed Web of Science ®Google Scholar
• Chaplin TM, Hong K, Fox HC, et al. Behavioral arousal in response to stress and drug cue in alcohol and cocaine addicted individuals versus healthy controls. Hum Psychopharmacol 2010;25:368-76
   PubMed Web of Science ®Google Scholar
• Greeley JD, Swift W, Prescott J, et al. Reactivity to alcohol-related cues in heavy and light drinkers. J Stud Alcohol 1993;54:359-68
   PubMed Web of Science ®Google Scholar
• Laberg JC. Alcohol and expectancy: subjective, psychophysiological and behavioral responses to alcohol stimuli in severely, moderately and non-dependent drinkers. Br J Addict 1986;81:797-808
   PubMedGoogle Scholar